Currently, there are 3.37B common shares owned by the public and among those 3.36B shares have been available to trade.
The company’s stock has a 5-day price change of -5.11% and -30.08% over the past three months. NVO shares are trading -32.48% year to date (YTD), with the 12-month market performance down to -52.95% lower. It has a 12-month low price of $59.32 and touched a high of $148.15 over the same period. NVO has an average intraday trading volume of 8.64 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -13.32%, -24.67%, and -44.95% respectively.
Institutional ownership of Novo Nordisk ADR (NYSE: NVO) shares accounts for 10.13% of the company’s 3.37B shares outstanding.
It has a market capitalization of $195.39B and a beta (3y monthly) value of 0.68. The stock’s trailing 12-month PE ratio is 17.69, while the earnings-per-share (ttm) stands at $3.28. The company has a PEG of 0.90 and a Quick Ratio of 0.55 with the debt-to-equity ratio at 0.72. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.91% over the week and 3.63% over the month.
Earnings per share for the fiscal year are expected to increase by 24.37%, and 21.60% over the next financial year. EPS should shrink at an annualized rate of 19.63% over the next five years, compared to 21.74% over the past 5-year period.
Looking at the support for the NVO, a number of firms have released research notes about the stock. BMO Capital Markets stated their Market Perform rating for the stock in a research note on April 17, 2025, with the firm’s price target at $64. Bernstein on their part issued Mkt Perform rating on January 06, 2025.
